Robert Owen Hughes

USPTO Granted Patents = 23 (Patent Applications = 14)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

Eureka, MO (US) (2007 - 2015)
Newtown, CT (US) (2016 - 2024)

Company Filing History:

8 out of 8

Disarm Therapeutics, Inc.

patents

7 out of 1,535

Boehringer Ingelheim International Gmbh

Elan Pharmaceuticals, Inc.

patents

5. 2 out of 523

Pharmacia & Upjohn Company

patents

6. 2 out of 1,579

Washington University

patents

7. 1 out of 4,442

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448374 - Inhibitors of SARM1 (2025-10-21),

2. 12441719 - Inhibitors of SARM1 (2025-10-14),

3. 12435084 - Indazole derivatives as inhibitors of SARM1 (2025-10-07),

4. 12338238 - Inhibitors of SARM1 (2025-06-24),

5. 12331033 - Inhibitors of SARM1 (2025-06-17),

6. 12083114 - Inhibitors of SARM1 in combination with neuro-protective agents (2024-09-10),

7. 12043613 - Inhibitors of SARM1 (2024-07-23),

8. 11903935 - Inhibitors of SARM1 NADase activity and uses thereof (2024-02-20),

9. 11358967 - Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma (2022-06-14),

10. 11253503 - Inhibitors of SARM1 NADase activity and uses thereof (2022-02-22),

11. 10954215 - Compounds as modulators of ROR gamma (2021-03-23),

12. 10815213 - Bruton's tyrosine kinase inhibitors (2020-10-27),

13. 10450314 - Pteridine derivatives as modulators of ROR gamma (2019-10-22),

14. 10266513 - Bruton's tyrosine kinase inhibitors (2019-04-23),

15. 9745297 - Compounds as modulators of RORC (2017-08-29),

Title: Robert Owen Hughes: Innovator in Neurodegeneration Treatments

Introduction

Robert Owen Hughes, based in Newtown, Connecticut, is a distinguished inventor with a strong focus on neurodegenerative disease research. With a total of 19 patents to his name, Hughes has made significant contributions to science and medicine, particularly in the area of inhibitors relevant to nerve health.

Latest Patents

Among his latest innovations, Hughes has developed compounds aimed at inhibiting SARM1, a critical target for preventing axonal degeneration. His work includes methods designed to treat and prevent neurodegenerative diseases by employing combinations of SARM1 inhibitors and neuroprotective agents. These advancements show promise in providing new therapeutic options for individuals facing the challenges of neurodegeneration.

Career Highlights

Throughout his career, Hughes has been associated with prominent companies in the biopharmaceutical sector, such as Boehringer Ingelheim International GmbH and Disarm Therapeutics, Inc. These experiences have allowed him to foster innovation and collaborate on groundbreaking research aimed at addressing significant health concerns.

Collaborations

Hughes has worked alongside esteemed colleagues including Rajesh Devraj and Xiang Li. These collaborations have greatly reinforced his efforts in developing effective treatment options for neurodegenerative conditions.

Conclusion

Robert Owen Hughes stands out as a prominent inventor whose work continues to push the boundaries of innovation in neuroscience. Through his numerous patents and collaborative projects, he is paving the way for new therapies that may change the landscape of treatment for neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.